ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Cancer Training Programs Fairing Fairley Well

December 1, 1989

In Brief: Schmidt Advises Upton To Consider Moving Control Projects In Other Division To DCCR

December 2, 1977

NCI Programs: NCI Seeks Nominations For director’s Consumer Liaison Group

August 6, 1999

In Brief: Hohn Named President, CEO Of Roswell Park; Mendelsohn Honored; AACE Elects Officers

February 7, 1997

Epstein Petition Seeks Broder’s Removal As NCI Director

February 5, 1993

Senate Committee Investigating Pharma’s “Educational Grants.”

January 20, 2006